thoracic_laptop
thoracic_phone

Schedule of Events

Individual faculty disclosures are linked to their names in the Schedule of Events below. You may also view all faculty disclosures at once.


Wednesday, March 15, 2017

4:00 p.m. - 6:00 p.m. 
Registration

Thursday, March 16, 2017 

7:00 a.m. - 5:30 p.m.
Registration

7:00 a.m. - 8:00 a.m. 
Continental Breakfast in the Exhibit Hall

7:50 a.m. - 8:00 a.m.
Day One Welcome
Zhongxing Liao, MD, MD Anderson Cancer Center, Houston  

8:00 a.m. - 9:30 a.m.
General Session I: Screening, Diagnosis and Staging
Moderator: Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia 

9:30 a.m. - 10:00 a.m.
Coffee Break in the Exhibit Hall

10:00 a.m. - 10:30 a.m.
Keynote I: Personalized Surgical Approaches to Therapy  
Moderator and Speaker: Mark K. Ferguson, MD, University of Chicago, Chicago

10:30 a.m. - 12:00 p.m. 
Plenary Session
Moderator: Zhongxing Liao, MD, MD Anderson Cancer Center, Houston

  • 1: Heterogeneity and variation in resistance mechanisms among 223 EGFR-mutant NSCLC patients with > 1 post-resistance biopsy
    Zofia Piotrowska, MD, Massachusetts General Hospital Cancer Center, Boston
  • 2: Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)
    Martin Edelman, MD, University of Maryland School of Medicine, Baltimore, Maryland
  • 3: Prospective Trial of Circulating Tumor Cells as a Biomarker for Early Detection of Recurrence in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Chemoradiation
    Chimbu Chinniah, University of Pennsylvania, Philadelphia
  • Discussant
    Ravi Salgia, MD, PhD, City of Hope, Duarte, California
  • 4: A Phase 2 Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node-negative, Peripheral Non-small Cell Lung Cancer
    Anurag Singh, MD, Roswell Park Cancer Institute, Buffalo, New York
  • 5: Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy
    Jennifer Ho, MD, MD Anderson Cancer Center, Houston
  • 6: Individualizing Radiation Dose in Locally Advanced Non-small Cell Lung Cancer Patients Using Pretreatment Serum MicroRNA Signatures
    Shruti Jolly, MD, University of Michigan, Ann Arbor, Michigan
  • Discussant 
    Jeffrey D. Bradley, MD, Washington University School of Medicine, St. Louis

12:00 p.m. - 1:00 p.m. 
Lunch in the Exhibit Hall

1:00 p.m. - 3:00 p.m.
General Session II: Early-stage Thoracic Cancers 
Moderator: David T. Cooke, MD, FACS, UC Davis Health System, Sacramento, California

3:00 p.m. - 3:30 p.m.
Coffee Break in the Exhibit Hall

3:30 p.m. - 5:30 p.m.
General Session III: Locally Advanced Stage III Cancer 
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle 

5:30 p.m. - 6:30 p.m.
Poster Viewing Session and Reception in the Exhibit Hall

Friday, March 17, 2017

7:00 a.m. - 6:00 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast in the Exhibit Hall

7:55 a.m. - 8:00 a.m.
Day Two Welcome
Jessica S. Donington, MD, New York University Cancer Center, New York

8:00 a.m. - 10:00 a.m.
General Session IV: Practical Guidance in Precision Medicine – Bridging the Gap Between Research and the Clinic 
Moderator: Zhongxing Liao, MD, MD Anderson Cancer Center, Houston

  • Deep Sequencing and Genomic Testing to Guide Therapy: Current Applications to Clinical Practice
    Ramaswamy Govindan, MD, Washington University School of Medicine, St. Louis
  • The Lung Cancer Precision Medicine Trials: Alchemist and LungMAP
    Karen Kelly, MD, University of California, Davis, Sacramento, California
  • Tumor Genomic Signatures and Targeted Pathways in Lung Cancer: Practical Considerations and the View from the Bench
    Arul Chinnaiyan, MD, PhD, University of Michigan Health System, Ann Arbor, Michigan
  • Liquid Biopsies/Cell-free DNA
    Maximilian Diehn, MD, PhD, Stanford School of Medicine, Stanford, California 
  • Q and A/Discussion

10:00 a.m. - 10:30 a.m.
Coffee Break in the Exhibit Hall

10:30 a.m. - 11:00 a.m.
Keynote II: Clinical Trials in Non-small Cell Lung Cancer - Lessons Learned and the Path Forward
 
Moderator: Jeffrey D. Bradley, MD, Washington University School of Medicine, St. Louis
Speaker: Walter J. Curran, MD, Emory University, Atlanta  

11:00 a.m. - 12:30 p.m.
Oral Abstract Session

Moderator: Jeffrey D. Bradley, MD, Washington University School of Medicine, St. Louis

  • 7: Tumor Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-small Cell Lung Cancer
    Boris Sepesi, MD, MD Anderson Cancer Center, Houston
  • 8: Indications for Invasive Mediastinal Staging in Patients with Early Non-small Cell Lung Cancer Staged with PET-CT
    Sarah Gao, Yale University School of Medicine, New Haven, Connecticut
  • 9: Racial Disparities in the Treatment and Outcome of Stage I Non-small Cell Lung Cancer
    Shraddha Dalwadi, MBA, Texas A and M College of Medicine/Scott and White Memorial Hospital, Temple, Texas
  • Discussant
    Jessica S. Donington, MD, New York University Cancer Center, New York
  • 10: Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors among Patients with Lung Cancer
    Kamran Ahmed, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
  • 11: Impact of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small Cell Lung Cancer: A Propensity Score Matched Analysis of Patients in the National Cancer Database 
    Sonam Sharma, MD, University of Pennsylvania, Philadelphia
  • 12: Standardization of Radiation Therapy Dose for Locally-advanced Non-small Cell Lung Cancer (NSCLC) through Changes to a Lung Cancer Clinical Pathway in a Large, Integrated Comprehensive CancerCenter Network
    Brian Gebhardt, MD, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
  • 13: Impact of Unfavorable Factors on Outcomes Among Inoperable Stage II-IV Non-small Cell Lung Cancer Patients Treated with Proton Therapy
    He Zhu, MD, PhD, University of Florida, Gainesville, Florida
  • Discussant
    Ramesh Rengan, MD, PhD, University of Washington, Seattle

12:30 p.m. - 1:30 p.m.  
Lunch in the Exhibit Hall 

Trainee and Early-career Networking Luncheon in Salons 10-11

1:30 p.m. - 3:00 p.m.
General Session V: Advanced Non-small Cell Lung Cancer, Part I - Targeted Therapy and Immunotherapy 
Moderator: Heather Wakelee, MD, Stanford University Medical Center, Stanford, California

  • Targeted Therapy and Management of Acquired Drug Resistance
    Lecia V. Sequist, MD, MPH, Massachusetts General Hospital, Boston
  • Immunotherapy: How to Apply in Practice, Choosing Patients and Management of Side Effects
    Hossein Borghaei, DO, Fox Chase Cancer Center, Philadelphia
  • Immunotherapy: Management of Early and Delayed Progression
    Heather Wakelee, MD, Stanford University Medical Center, Stanford, California

3:00 p.m. - 3:30 p.m. 
Coffee Break in the Exhibit Hall

3:30 p.m. - 5:00 p.m.
General Session V: Advanced Non-small Cell Lung Cancer, Part II
Moderator: Daniel R. Gomez, MD, MD Anderson Cancer Center, Houston

5:00 p.m. - 6:00 p.m.
Tumor Board: Advanced Non-small Cell Lung Cancer
 
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California

Panelists:

Saturday, March 18, 2017

7:00 a.m. - 12:00 p.m.
Registration

7:00 a.m. - 8:00 a.m. 
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Three Welcome
 
Ramesh Rengan, MD, PhD, University of Washington, Seattle  

8:00 a.m. - 9:30 a.m.
General Session VI: Other Thoracic Tumors 
Moderator: Zhongxing Liao, MD, MD Anderson Cancer Center, Houston

9:30 a.m. - 10:00 a.m.
Coffee Break

10:00 a.m. - 10:30 a.m.
Keynote III: Immunotherapeutic Strategies for Management of Lung Cancer
 
Moderator: Naiyer A. Rizvi, MD, Columbia University Medical Center, New York
Speaker: Julie R. Brahmer, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore  

10:30 a.m. - 12:00 p.m.
General Session VII: Immunotherapy in Lung Cancer
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle

  • Immunotherapy: Pushing the Frontier Past Immune Checkpoint Inhibition
    Naiyer A. Rizvi, MD, Columbia University Medical Center, New York
  • Radiation and Immune Modulation: Moving Radiation Beyond Local Control
    Ramesh Rengan, MD, PhD, University of Washington, Seattle
  • The Value Proposition in the Era of Immunotherapeutics and Precision Medicine: How to Stay on the Leading Edge of Cancer Care while Being a Responsible Steward of Health Care Dollars
    Daniel R. Gomez, MD, MD Anderson Cancer Center, Houston
  • Q and A/Discussion 
 
Copyright © 2016 American Society for Radiation Oncology | Conflict of Interest | Terms of Use | Privacy Policy | Contact Us 
251 18th Street South, 8th Floor, Arlington, VA 22202 | Phone: 703.502.1550 | Fax: 703.502.7852